Seminars in Oncology Nursing
Volume 22, Issue 4 , Pages 249-256 , November 2006

Radioprotectants: Adding Quality of Life to Survivorship?

  • Vanna M. Dest

      Affiliations

    • Corresponding Author InformationAddress correspondence to Vanna M. Dest, MSN, APRN, BC, AOCN®, Hospital of Saint Raphael/New Haven Radiology, PC, Father Michael J. McGivney Center for Cancer Care, 1450 Chapel St, New Haven, CT 06511

References 

  1. Gosselin-Acomb T. Principles of radiation therapy. In:  Yarbro CH,  Frogge MH,  Goodman M editor. Cancer Nursing: Principles & Practice. Ed 6. Sudbury, MA: Jones & Bartlett; 2005;p. 229–249
  2. American Society of Clinical Oncology. 2002 Update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002;20:2895–2903
  3. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590–2598
  4. Rubenstein EB, Peterson DE, Schubert M, et al. Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology: Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100:2026–2046
  5. Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol. 1999;26:3–21
  6. Dorr RT. Radioprotectants: Pharmacology and clinical applications of amifostine. Semin Radiat Oncol. 1988;8:10–13
  7. Grdina DJ, Sigdestad CP. Radiation protectors: The unexpected benefits. Drug Metab Rev. 1989;20:13–42
  8. Calabro-Jones PM, Aguilera JA, Ward JF, et al. Uptake of WR-2721 derivatives by cells in culture: Identification of the transported form of the drug. Cancer Res. 1988;48:3634–3640
  9. Ethyol product information. In: Selective Cytoprotection booklet. Gaithersburg, MD, Med Immune, 2003;1-27.
  10. Grdina DJ, Kataoka Y, Murley JS. Amifostine mechanisms of action underlying cytoprotection and chemoprevention. Drug Metab Drug Interact. 2000;16:237–279
  11. Capizzi RL. Clinical status and optimal use of amifostine. Oncology. 1999;13:47–59
  12. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2 (3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res. 1980;40:1519–1524
  13. Alden ME, O’Reilly RC, Topham A, et al. Elapsed radiation therapy treatment time as a predictor of survival in patients with advanced head and neck cancer who receive chemotherapy and radiation therapy. Radiology. 1996;201:675–680
  14. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30
  15. Berk LB, Shivani AT, Small W. Pathophysiology and management of radiation-induced xerostomia. J Support Oncol. 2005;3:191–200
  16. Samuels MA. Cytoprotection in head and neck cancer: Issues in oral care. J Support Oncol. 2004;2:9–12
  17. Sonis ST. Oral mucositis in cancer therapy. J Support Oncol. 2004;2:3–8
  18. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotectant in head and neck cancer. J Clin Oncol. 1999;18:147–148
  19. Antonadou D, Pepelassi M, Synodinou M, et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head and neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:739–747
  20. Hensley ML, Schucter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999;17:3333–3335
  21. Antonadou D, Pepelassi E, Synodinou M, et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head and neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:739–747
  22. Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol. 2000;18:2226–2233
  23. Gopal R. Non–small cell lung cancer: The role of cytoprotection in treating therapy-related toxicity. J Supp Oncol. 2005;2(suppl 3):13–17
  24. Antonadou D, Synodinou M, Boufi M, et al. Amifostine reduces acute toxicity during radiochemotherapy in patients with localized advanced stage non–small cell lung cancer. [abstr 1960] Proc Am Soc Clin Oncol. 2000;19:1953a
  25. Komaki R, Lee JS, Kaplan B, et al. Randomized phase III study of chemoradiation ± amifostine in patients with inoperable stage II-III non–small cell lung cancer. [abstr 1298] Proc Am Soc Clin Oncol. 2001;20:258b
  26. Gopal R, Starkschall G, Tucker S. The effects of radiation therapy, chemotherapy and the radioprotector amifostine on the diffusion capacity of patients with non–small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2001;51:114–120
  27. Komaki R, Lee JS, Milas L, et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non–small cell lung cancer: Report of a randomized comparative. Int J Radiat Oncol Biol Phys. 2004;58:1369–1377
  28. Komaki R. What should the optimal timing be for amifostine administration relative to radiation and chemotherapy?. J Clin Oncol. 2005;23:7232–7233
  29. Athanassiou H, Antonadou D, Coliarakis N, et al. Oncology Hellenic Group: Protective effects of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: Results of a randomized trial. Int J Radiat Oncol Biol Phys. 2003;56:1154–1160
  30. Sasse AD, Clark LGO, Sasse EC, et al. Amifostine reduces side effects and improves complete response rate during radiotherapy: Results of a meta-analysis. Int J Radiat Oncol Biol Phys. 2006;64:784–791

PII: S0749-2081(06)00099-4

doi: 10.1016/j.soncn.2006.07.009

Seminars in Oncology Nursing
Volume 22, Issue 4 , Pages 249-256 , November 2006

Article Tools

* Image Usage & Resolution